Scale-up and Manufacturing of Clinical-grade Self-inactivating γ-retroviral Vectors by Transient Transfection

Overview

Journal Gene Ther

Date 2011 Jul 15

PMID 21753795

Citations 17

Authors

J C M van der Loo

W P Swaney

E Grassman

A Terwilliger

T Higashimoto

A Schambach

C Baum

A J Thrasher

D A Williams

D L Nordling

L Reeves

P Malik

Affiliations

Soon will be listed here.

Abstract

The need for γ-retroviral (gRV) vectors with a self-inactivating (SIN) design for clinical application has prompted a shift in methodology of vector manufacturing from the traditional use of stable producer lines to transient transfection-based techniques. Herein, we set out to define and optimize a scalable manufacturing process for the production of gRV vectors using transfection in a closed-system bioreactor in compliance with current good manufacturing practices (cGMP). The process was based on transient transfection of 293T cells on Fibra-Cel disks in the Wave Bioreactor. Cells were harvested from tissue culture flasks and transferred to the bioreactor containing Fibra-Cel in the presence of vector plasmid, packaging plasmids and calcium-phosphate in Dulbecco's modified Eagle's medium and 10% fetal bovine serum. Virus supernatant was harvested at 10-14 h intervals. Using optimized procedures, a total of five ecotropic cGMP-grade gRV vectors were produced (9 liters each) with titers up to 3.6 × 10(7) infectious units per milliliter on 3T3 cells. One GMP preparation of vector-like particles was also produced. These results describe an optimized process for the generation of SIN viral vectors by transfection using a disposable platform that allows for the generation of clinical-grade viral vectors without the need for cleaning validation in a cost-effective manner.

Citing Articles

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.

Altvater B, Kailayangiri S, Spurny C, Flugge M, Meltzer J, Greune L Cancer Gene Ther. 2023; 30(10):1355-1368.

PMID: 37391502 PMC: 10581901. DOI: 10.1038/s41417-023-00642-x.

Process intensification for lentiviral vector manufacturing using tangential flow depth filtration.

Tona R, Shah R, Middaugh K, Steve J, Marques J, Roszell B Mol Ther Methods Clin Dev. 2023; 29:93-107.

PMID: 36994313 PMC: 10041461. DOI: 10.1016/j.omtm.2023.02.017.

T cell-responsive macroporous hydrogels for in situ T cell expansion and enhanced antitumor efficacy.

Bhatta R, Han J, Liu Y, Bo Y, Wang H Biomaterials. 2022; 293:121972.

PMID: 36566554 PMC: 9868092. DOI: 10.1016/j.biomaterials.2022.121972.

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors.

Tan E, Chin C, Lim Z, Ng S Front Bioeng Biotechnol. 2021; 9:796991.

PMID: 34966729 PMC: 8711270. DOI: 10.3389/fbioe.2021.796991.

Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.

Abou-El-Enein M, Elsallab M, Feldman S, Fesnak A, Heslop H, Marks P Blood Cancer Discov. 2021; 2(5):408-422.

PMID: 34568831 PMC: 8462122. DOI: 10.1158/2643-3230.BCD-21-0084.

References

Naldini L, Blomer U, Gage F, Trono D, Verma I . Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 1996; 93(21):11382-8. PMC: 38066. DOI: 10.1073/pnas.93.21.11382. View

Grez M, Akgun E, Hilberg F, Ostertag W . Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci U S A. 1990; 87(23):9202-6. PMC: 55132. DOI: 10.1073/pnas.87.23.9202. View

Wilson J . Gendicine: the first commercial gene therapy product. Hum Gene Ther. 2005; 16(9):1014-5. DOI: 10.1089/hum.2005.16.1014. View

Howe S, Mansour M, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H . Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008; 118(9):3143-50. PMC: 2496964. DOI: 10.1172/JCI35798. View

Kraunus J, Schaumann D, Meyer J, Modlich U, Fehse B, Brandenburg G . Self-inactivating retroviral vectors with improved RNA processing. Gene Ther. 2004; 11(21):1568-78. DOI: 10.1038/sj.gt.3302309. View

Nordling D, Kaiser A, Reeves L . Release testing of retroviral vectors and gene-modified cells. Methods Mol Biol. 2008; 506:265-79. DOI: 10.1007/978-1-59745-409-4_18. View

Schambach A, Galla M, Maetzig T, Loew R, Baum C . Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther. 2007; 15(6):1167-73. DOI: 10.1038/sj.mt.6300152. View

Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C . Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006; 24(6):687-96. DOI: 10.1038/nbt1216. View

Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E . Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther. 2008; 16(4):718-25. DOI: 10.1038/mt.2008.5. View

10.

Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack M, Wulffraat N, Leboulch P . LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302(5644):415-9. DOI: 10.1126/science.1088547. View

11.

Schambach A, Bohne J, Chandra S, Will E, Margison G, Williams D . Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther. 2005; 13(2):391-400. DOI: 10.1016/j.ymthe.2005.08.012. View

12.

Graham F, Van Der Eb A . A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973; 52(2):456-67. DOI: 10.1016/0042-6822(73)90341-3. View

13.

Baum C, Hegewisch-Becker S, ECKERT H, Stocking C, Ostertag W . Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol. 1995; 69(12):7541-7. PMC: 189692. DOI: 10.1128/JVI.69.12.7541-7547.1995. View

14.

Segura M, Garnier A, Kamen A . Purification and characterization of retrovirus vector particles by rate zonal ultracentrifugation. J Virol Methods. 2005; 133(1):82-91. DOI: 10.1016/j.jviromet.2005.10.030. View

15.

Feng Y, Liu Z, Cao H, Meng X, Qu Z, Xiong M . Construction of eukaryotic expression plasmid of human PRX3 and its expression in HEK-293FT cells. J Huazhong Univ Sci Technolog Med Sci. 2004; 24(4):311-3, 321. DOI: 10.1007/BF02861855. View

16.

Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H . A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther. 2009; 17(2):272-80. DOI: 10.1038/gt.2009.134. View

17.

Merten O . State-of-the-art of the production of retroviral vectors. J Gene Med. 2004; 6 Suppl 1:S105-24. DOI: 10.1002/jgm.499. View

18.

Herbst F, Ball C, Zavidij O, Fessler S, Schmidt M, Veelken H . 10-year stability of clinical-grade serum-free γ-retroviral vector-containing medium. Gene Ther. 2010; 18(2):210-2. DOI: 10.1038/gt.2010.126. View

19.

. Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther. 2001; 12(3):303-14. DOI: 10.1089/10430340150218431. View

20.

Felgner P, Gadek T, Holm M, Roman R, Chan H, Wenz M . Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987; 84(21):7413-7. PMC: 299306. DOI: 10.1073/pnas.84.21.7413. View